
Incubator invests in two oncology start-ups
Oslo Cancer Cluster Incubator has become a shareholder in Oncosyne and Immunoquest, two start-ups developing new approaches to more precise cancer treatments.

Oslo Cancer Cluster Incubator has become a shareholder in Oncosyne and Immunoquest, two start-ups developing new approaches to more precise cancer treatments.

Engasjement, sterke budskap og imponerende formidlingsevne preget skolefinalen i «Ta ordet» konkurransen ved Ullern videregående skole. Ni klassevinnere konkurrerte om å holde den beste argumenterende talen om alt fra kroppspress og likestilling til ytringsfrihet, trygghet og arbeidsvilkår.

NordicRWE, a member of Oslo Cancer Cluster, has received NOK 16 million to develop new ways of using Nordic health data to accelerate drug development.

Oslo Cancer Cluster member Thor Medical has opened AlphaOne, a new facility at Herøya for producing isotopes for targeted cancer treatments.

Oslo Cancer Cluster takes over the podcast Radium, expanding its focus on innovation, collaboration and the people driving change in the cancer field.

Andre utflukt for de 19 elevene som tar Medisinsk Innovasjon som fordypning i første klasse ved Ullern videregående skole, gikk til Radiumhospitalet for å lære mer om protonbehandling. Det ble et inspirerende besøk for både elevene og omviser Jonas Asperud, som er medisinsk fysiker ved senteret.
Get monthly news updates and invitations to events from our oncology cluster.

Ketil Widerberg slutter i Oslo Cancer Cluster etter 12 år som leder av Norges eldste helseklynge.

New funding will help Oncoinvent advance its ovarian cancer programme and prepare for Phase III development.

Oslo Cancer Cluster takes a key role in a major European initiative that aims to strengthen cancer collaboration across countries and connect partners beyond the EU.

A new science specialisation at Ullern Upper Secondary School will give students first-hand experience of medical research and innovation.

From Tehran to Oslo, how one researcher is developing a new weapon against treatment-resistant cancers.

With offices in Norway, Sweden and Denmark, NordicRWE wants to strengthen collaboration on health data and cancer innovation.

